Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Sees Wider Loss, Flatter Revenue, Increased Spending in Q4

NEW YORK, Jan. 22 - Millennium Pharmaceuticals on Tuesday said that fourth-quarter losses widened as revenue fell and spending on new drug development increased.

Net loss for the quarter ended Dec. 31grew by 79 percent to $66.97 million, or 30 cents a share, from $37.49 million, or 18 cents, in the same period last year.

Revenue, meanwhile, slumped 7 percent to $54.6 million from $58.7 million year over year. Millennium blamed contracting milestone payments from partnerships with pharmaceutical companies.

The company posted a loss of $50.4 million, or 23 cents a share, from a loss of $15.6 million, or 7 cents, one year ago. Analysts polled by Thomson Financial/First Call thought the company would post a loss of between 12 cents and 26 cents a share with an average estimate of 19 cents. The losses excluded amortization charges, debt conversion expenses, the cost of an accounting change, and deemed preferred-stock dividend, Millennium said.

Cambridge, Mass.-based Millennium, which like many former genomic tool and tech companies, has been flirting with a drug-developer model. Though it's aiming at robust clinical categories--inflammatory, metabolic, and cancer--it has not yet developed a single product.

But there are other ways of generating income while you wait for your product pipeline to bear fruit. In December, Millennium said it intends to acquire COR Therapeutics for roughly $2 billion explicitly for COR's anti-clotting product Integrilin.

Millennium reiterated its intention to exceed $400 million in total revenue in 2002.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.